Stella Pharmaceutical

Stella Pharma Corporation is a Japanese biopharmaceutical company specializing in the development of Boron Neutron Capture Therapy (BNCT), a precision cancer treatment modality. The company's flagship product, Steboronine (borofalan (10B)), is the world's first boron drug approved for BNCT, specifically indicated for unresectable advanced or recurrent head and neck cancer. Stella Pharma leverages the high selectivity of boron compounds to target tumor cells via the LAT1 transporter, followed by low-energy neutron irradiation to induce localized cell death while sparing healthy tissue. The company is actively expanding its clinical pipeline to include indications such as malignant glioma and skin cancers, while collaborating with medical device partners to establish BNCT centers globally.